Edgewise Therapeutics Stock Forecast

Stock Price Forecast

According to 12 analysts polled by S&P Global, Edgewise Therapeutics stock has a consensus rating of "Buy" and an average price target of $48.17. The average 1-year stock price forecast is 17.63% higher than the current stock price, while the lowest is $30 (-26.74%) and the highest is $66 (+61.17%).

Price Target: $48.17 (+17.63%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$30	$48.17	$51.5	$66
Change	-26.74%	+17.63%	+25.76%	+61.17%

Analyst Ratings

The average analyst rating for Edgewise Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	7	7	7	7	7	7
Buy	3	3	3	3	3	2
Hold	2	2	2	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	12	12	12	12	12	11

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Laura Chico Wedbush	Wedbush	Buy Maintains $52	Buy	Maintains	$52	+26.98%	Jun 17, 2026
Srikripa Devarakonda Truist Financial	Truist Financial	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Jun 17, 2026
Leonid Timashev RBC Capital	RBC Capital	Buy Reiterates $48 → $59	Buy	Reiterates	$48 → $59	+44.08%	Jun 17, 2026
Debjit Chattopadhyay Guggenheim	Guggenheim	Buy Maintains $41	Buy	Maintains	$41	+0.12%	Jun 17, 2026
Paul Choi Goldman Sachs	Goldman Sachs	Hold Reiterates $20 → $32	Hold	Reiterates	$20 → $32	-21.86%	Jun 17, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

209.38M

Revenue Next Year

52.50M

from 209.38M

-74.93%

from 209.38M

EPS This Year

1.28

from -1.63

EPS Next Year

-1.42

from 1.28

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	209.38M
Operating Income	-43.22M	-71.66M	-114.36M	-158.83M	-191.41M	20.38M
Net Income	-42.81M	-67.64M	-100.16M	-133.81M	-167.80M	-26.26M
EPS	-	-	-	-	-1.63	1.28
Forward PE	-	-	-	-	-	32.08
Free Cash Flow	-19.26M	-35.48M	-61.66M	-63.22M	-87.34M	-443.00M
No. Analysts	-	-	-	-	-	8

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	1.7B
Avg	209.4M
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-4.5%
Avg	-74.9%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	10.34
Avg	1.28
Low	-2.34

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-